Neuromodulation
DeviceNeuromodulation
NCT Number: NCT05414955
Feasibility study of neuromodulation in patients with IBD.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Phillip Fleshner, Inc., Los Angeles, California, United States
The study will evaluate responses of patients with IBD treated with neuromodulation at various intervals.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
General Inclusion Criteria:
General Exclusion Criteria (The subject must not meet ANY of the following criteria):
Neuromodulation
Time frame: up to 1 year
CDAI (Crohn's Disease Activity Index Score) or MAYO Score (ulcerative colitis)
Boomerang Medical
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06381518
Colitis, Colitis, Ulcerative
Sittard, Netherlands
View Trial DetailsNCT06023667
Colitis, Colitis, Ulcerative
Cincinnati, Ohio, United States
View Trial DetailsNCT01369355
Colitis, Colonic Diseases
Tucson, Arizona, United States
View Trial DetailsNCT06742203
IBD
Jerusalem, Israel
View Trial Details